Skip to main content

Table 2 Metabolites associated with COPD in the discovery and replication studies

From: A cross-omics integrative study of metabolic signatures of chronic obstructive pulmonary disease

Metabolite Discovery meta-analysis Replication meta-analysis
β SE OR P-value Directiona N β SE OR P-value Directionb N
GlycA 0.152 0.044 1.16 5.6 × 10−4 ++++ 5557 0.266 0.053 1.30 1.8 × 10−6 +++ 12,205
3-hydroxybutyrate 0.122 0.041 1.13 0.003 ++++ 5002 −0.031 0.057 0.97 0.662 − − + 12,173
Histidine −0.097 0.047 0.91 0.037 − − − −  5534 −0.153 0.063 0.86 0.020 −−− 12,200
Free cholesterol in med. HDL 0.099 0.049 1.10 0.045 + − ++ 5557 0.004 0.063 1.00 0.867 − − + 12,208
Acetoacetate 0.084 0.042 1.09 0.047 ++ − + 5551 −0.061 0.059 0.94 0.360 −−− 12,204
18:2, linoleic acid −0.095 0.048 0.91 0.049 + −−−  5546 −0.036 0.057 0.96 0.238 + − + 12,167
  1. Model adjusted for age, sex, BMI, LLM use and smoking status; GlycA Glycoprotein acetyls, HDL high density lipoprotein, β effect size, SE standard error, OR odds ratio; Direction - direction of the effect in individual studies; N - meta-analysis sample size; a Direction of the effect in the discovery studies in order: ERF, RS-III-2, RS-E5, RS-I-4; b Direction of the effect in the replication studies in order: LLDEEP, FINRISK97, DILGOM; In bold: significant results (P < 0.001)